| Zyprexa Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Zyprexa 20 mg | tablet | oral | 1.0 each | OTC |
| Zyprexa 5 mg | tablet | oral | 1.0 each | OTC |
| Zyprexa 7.5 mg | tablet | oral | 1.0 each | OTC |
| Zyprexa 2.5 mg | tablet | oral | 1.0 each | OTC |
| Zyprexa 10 mg | tablet | oral | 1.0 each | OTC |
| Zyprexa 15 mg | tablet | oral | 1.0 each | OTC |
| Zyprexa 10 mg | powder for injection | intramuscular | 1.0 each | OTC |
Posted by perseverance 14 days ago
I was on Zyprexa a few years back and I gained a lot of weight with it due to increased appetite. In my case this was not a p...
Posted by ebonyrae 4 months ago
I have been on zyprexa for about 2 1/2 years I have tried 3 times to get off it, but each time have had bad anxiety and panic...
Posted by pianobassgirl 12 months ago
I only took Zyprexa once every week b/c of severe insomnia and sometimes 2x's a months w/ 3 days intervals to catch up on sle...
In Trial, Alaska Says Lilly Concealed Risks of a Schizophrenia Drug - New York Times
By ALEX BERENSON ANCHORAGE — Eli Lilly, the drug maker, systematically hid the risks and side effects of Zyprexa, its best-selling schizophrenia medicine, ...
Wed Mar 05 22:12:27 -0500 2008
Lilly cancels inhalable-insulin trials - Louisville Courier-Journal
Another drug developed by Lilly is Zyprexa, which is prescribed to treat schizophrenia and bipolar disorder. Zyprexa, which brought in $4.8 billion in sales ...
Sun Mar 09 05:54:45 -0400 2008
Legal Showdown in Alaska Over Zyprexa Risks in Alaska - Wall Street Journal
The state contends Lilly concealed the risks of diabetes and obesity from Zyprexa to protect sales of the blockbuster. If that claim is proved, ...
Thu Mar 06 10:35:07 -0500 2008
olanzapine - A synthetic derivative of thienobenzodiazepine with antipsychotic properties. As a selective monoaminergic antagonist, olanzapine binds with high affinity binding to the following receptors: serotonin, dopamine, muscarinic M1-5, histamine H1, and alpha1-adrenergic receptors; it binds weakly to gamma-aminobutyric acid type A, benzodiazepine, and beta-adrenergic receptors. Although its exact mechanism of action in schizophrenia is unknown, it has been proposed that olanzapine's antipsychotic activity is mediated through a combination of dopamine and serotonin type 2 antagonism.